GPP vs GMP in Cannabis: What’s the Difference and Which Standard Does Your Market Require?

What does this mean for the global cannabis industry?

Two acronyms appear constantly in cannabis compliance discussions — GPP and GMP — and the confusion between them is not trivial. Using the wrong framework as your compliance baseline can mean failing a Health Canada inspection, losing an export contract, or investing in a certification program your target market does not actually require. The stakes are high enough that precision matters.

GPP — Good Production Practices — is a Canadian domestic standard, defined in law under Part 5 of the Cannabis Regulations (SOR/2018-144) and enforced exclusively by Health Canada. GMP — Good Manufacturing Practices — is a pharmaceutical quality standard with multiple international expressions, most relevantly EU GMP as codified in EudraLex Volume 4 (European Commission/EMA) and WHO GMP as published in the Technical Report Series. These are not interchangeable terms for the same thing. They are distinct regulatory frameworks with different authors, different scopes, and different consequences for non-compliance.

This guide unpacks both standards from their official sources, explains exactly how they differ, and helps compliance officers, quality managers, and operations directors determine which one — or which combination — their specific operation requires.

What Is GPP? The Canadian Domestic Standard

Legal Definition and Regulatory Home

Good Production Practices is not an industry term or a voluntary standard. In Canada, it is a precise legal concept created by federal regulation. Part 5 of the Cannabis Regulations (SOR/2018-144), sections 78.1 through 89, establishes the GPP framework that every federally licensed cannabis producer must meet.

Section 78.1 opens Part 5 with the definitions that govern the entire framework. It defines an acceptable level as "a level of a biological, chemical or physical hazard that does not present a risk of contamination," a control measure as "a measure that can be applied to prevent or eliminate any biological, chemical or physical hazard," and a critical control point as "a step at which the application of a control measure is essential to prevent or eliminate any biological, chemical" hazard. These definitions deliberately echo food safety hazard analysis language — a deliberate legislative choice that reflects the early positioning of cannabis closer to agriculture than to pharmaceutical manufacturing.

Section 79 establishes the foundational compliance gate: licence holders cannot sell, distribute, or export cannabis unless all requirements in sections 80 through 88.94 are satisfied. This is not aspirational — it is a condition of sale.

What GPP Requires: Core Obligations

The operational requirements under GPP span every stage of a licensed producer’s activities:

• Standard Operating Procedures (Section 80): Cannabis and any ingredient must be produced, packaged, labelled, distributed, stored, sampled, and tested in accordance with documented SOPs designed to ensure compliance with Part 5 and Part 6 of the Regulations.
• Pest control (Section 81): Only pest control products registered for cannabis use under the Pest Control Products Act may be applied, with specific exceptions for edible cannabis.
• Storage (Section 82): Cannabis and ingredients must be stored "under conditions that maintain their quality."
• Distribution (Section 83): Distribution must occur in a manner that maintains quality.
• Building standards (Section 84): Facilities must be "designed, constructed and maintained in a manner that permits those activities to be conducted appropriately and under sanitary conditions."
• Ventilation and filtration (Section 85): Systems must filter odours, provide adequate ventilation, withstand cleaning, and function as intended.
• Water supply (Section 85.1): Water systems must be appropriate for cannabis activities; potable water must be protected against cross-connection contamination.
• Lighting (Section 85.2): Appropriate lighting, with fixtures that withstand cleaning and do not create contamination risk if broken.
• Equipment (Section 86): Equipment must allow effective cleaning, function properly, prevent contamination, and protect against allergen cross-contamination.

Additional requirements for processing licence holders (Section 88) and testing requirements (Section 89) extend the framework to finished-product manufacturing and analytical verification.

Health Canada has published a Good Production Practices Guide for Cannabis to assist licensees in interpreting these requirements. The Guide makes clear that compliance requires two simultaneous elements: a written GPP program and active implementation with complete documentation. A well-written plan that is not being followed is non-compliant. A sound practice that is followed but not documented is equally non-compliant. Both elements must coexist.

Who GPP Applies To

GPP applies to all federally licensed cannabis producers in Canada — cultivation licences, processing licences, and sale licences — with narrow exemptions for analytical testing licence holders and research licence holders (Section 79.2). GPP is the mandatory baseline for domestic Canadian cannabis operations. It is not optional, and there is no tiered compliance pathway.

What Is GMP? The Pharmaceutical Standard for Export and Medical Markets

Legal Definition and Regulatory Home

Good Manufacturing Practices is a pharmaceutical quality paradigm with multiple authoritative sources. The three most relevant for cannabis operators are:

EU GMP — EudraLex Volume 4 (European Commission / EMA): The binding framework for all medicinal products manufactured or imported into the European Union. EudraLex Volume 4 is organized into Part I (basic requirements for medicinal products), Part II (active substances, equivalent to ICH Q7), and a series of Annexes. For cannabis specifically, Annex 7 (Manufacture of Herbal Medicinal Products) applies alongside Part I for finished cannabis medicines, and Part II applies to raw cannabis materials used as active pharmaceutical ingredients (APIs). The European Medicines Agency oversees this framework, and EU member state competent authorities conduct GMP inspections.

WHO GMP — Technical Report Series (TRS 986, Annex 2): The foundational international GMP standard, first adopted in 1968 and incorporated into the national medicines laws of more than 100 countries. TRS 986 Annex 2 ("WHO Good Manufacturing Practices for Pharmaceutical Products: Main Principles") establishes that medicinal products must be "consistently produced and controlled to the quality standards appropriate to their intended use." WHO GMP serves as the basis for the WHO Certification Scheme for pharmaceutical products in international commerce. For herbal medicines — the category most relevant to cannabis — WHO has published specific guidance under TRS 1010 Annex 2 (GMP for Manufacture of Herbal Medicines).

PIC/S GMP Guide — PE 009-17 (Pharmaceutical Inspection Co-operation Scheme): The primary harmonization instrument aligning GMP standards across 57 participating regulatory authorities. The current edition is PE 009-17 (released June 2023). PIC/S membership includes Health Canada, EMA, TGA (Australia), MHRA (UK), and dozens of others. A Canadian producer whose facility meets PIC/S PE 009-17 can generally demonstrate equivalency across most major export markets simultaneously.

What GMP Requires: Core Obligations

GMP is more demanding than GPP across every operational dimension. Key requirements include:

• Pharmaceutical Quality System (PQS): A documented, risk-based quality management system encompassing process validation, change control, deviation management, CAPA (Corrective and Preventive Action), and product quality reviews.
• Qualified Person (QP): EU GMP requires a named, legally accountable Qualified Person to certify each batch for release to market. No equivalent requirement exists under Canadian GPP.
• Validated processes and systems: All manufacturing processes, equipment, and computerized systems (including software) must be formally validated to demonstrate consistent performance. EudraLex Volume 4 Annex 11 governs computerized systems specifically.
• Batch documentation and records: Comprehensive batch manufacturing records, with complete traceability from starting material through finished product, reviewed and certified before batch release.
• Environmental monitoring: For controlled manufacturing environments, continuous monitoring of temperature, humidity, particulate counts, and microbial bioburden, with action and alert limits.
• Contract manufacturing and testing (Chapter 7): Formal written agreements governing any outsourced activity, with technical transfer protocols and ongoing oversight.
• Stability testing: Ongoing stability programs to confirm product quality through shelf life, supporting registered storage conditions and expiry dating.
• Third-party certification: EU GMP compliance is verified through inspection by a European competent authority (or a recognized mutual recognition partner) and results in a GMP certificate for each certified site. No certificate — no EU market access.

GPP vs GMP: Side-by-Side Comparison

Which Standard Does Your Operation Actually Need?

The answer depends on three variables: your licence type, your target markets, and your product category.

Scenario 1: Canadian Domestic Only — GPP Is Your Standard

If your operation grows, processes, or sells cannabis exclusively into the Canadian market — recreational or medical — your mandatory baseline is GPP under Part 5 of SOR/2018-144. Health Canada does not require EU GMP certification for domestic operations. Pursuing EU GMP voluntarily is not wrong, but it is a significant investment that does not unlock any additional domestic permissions.

The practical focus for domestic operators is building a genuine GPP program: documented SOPs for every production activity, evidence that those SOPs are followed consistently, and audit-ready records across all stages from cultivation through sale. Health Canada’s inspection program is risk-based, and documentation gaps are a common finding.

Scenario 2: Medical Export to EU, Germany, UK, or Australia — GMP Is Mandatory

This is where the distinction becomes commercially consequential. Canada exported 240 tonnes of cannabis in 2025, more than double the 107 tonnes exported in 2024, with Germany alone absorbing 93,006 kg (46% of total Canadian exports). Every kilogram of that product reached Europe because the exporting facility held a valid EU GMP certificate.

The EU will not accept cannabis medicinal products from a facility that cannot demonstrate EU GMP compliance. This is not a preference — it is a legal requirement under EU Directive 2001/83/EC governing medicinal products. The requirement applies to the manufacturing site, not just the finished product, which means GPP-only Canadian producers are categorically excluded from direct EU export.

Achieving EU GMP requires a fundamentally different operational investment: a documented Pharmaceutical Quality System, validated processes and computerized systems, a named Qualified Person for EU batch release, formal environmental controls, and a successful inspection by an EU member state competent authority. Canada and the EU maintain a Mutual Recognition Agreement (MRA) for pharmaceutical GMP inspections, which means Health Canada can conduct GMP inspections on behalf of EU regulators for Canadian facilities — an important pathway that reduces the duplication of on-site inspection.

Scenario 3: Pursuing Both — The Strategic Positioning

A growing cohort of Canadian licensed producers is pursuing EU GMP not because domestic regulations require it, but because it is the clearest signal of quality differentiation in an increasingly competitive market. There are currently 23 registered EU-GMP-certified Canadian cannabis facilities, all held by publicly traded companies — a structural advantage over smaller producers still operating at GPP baseline.

The strategic logic is sound: EU GMP certification simultaneously unlocks European export markets, positions the facility for Australian TGA-compliant export (Australia’s TGA is a PIC/S member and recognizes PIC/S-equivalent facilities), and creates a verifiable quality credential for premium domestic and international buyers. GPP compliance remains the regulatory floor; EU GMP becomes the commercial ceiling.

The GrowerIQ platform has been independently revalidated by RQC as meeting GxP-compliant standards — including alignment with EudraLex Volume 4 Annex 11 requirements governing computerized systems — making it one of the few cannabis production software platforms that supports both GPP and GMP compliance environments. You can read more about GrowerIQ’s GMP compliance validation and the specific EU GMP requirements it addresses.

Common Misconceptions That Create Compliance Risk

"GPP is just a lighter version of GMP." This framing is incorrect and can lead to under-investment in GPP programs. GPP is a distinct regulatory framework designed for cannabis — not a watered-down pharmaceutical standard. It has its own legal definitions, its own inspection regime, and its own compliance consequences. Treating it casually because it is "less than GMP" is how producers fail Health Canada inspections.

"GMP certification covers our Canadian GPP obligations." Also incorrect. GMP certification is issued by EU competent authorities or recognized inspection bodies against the EU GMP framework. It does not substitute for or satisfy Canadian GPP obligations under the Cannabis Regulations. A producer with full EU GMP certification still needs a functioning, documented GPP program to maintain their Canadian licence.

"We don’t need GMP because Health Canada regulates us." Health Canada does regulate Canadian producers — under GPP. Canada’s domestic regulatory framework does not require GMP certification. But if that producer wants to export medicinal cannabis to Germany, the Netherlands, or the UK, the importing jurisdiction’s regulatory framework applies to the product, and that jurisdiction requires GMP. The exporting country’s regulation governs domestic permissions; the importing country’s regulation governs market access.

"GACP is the same as GMP." A third acronym — Good Agricultural and Collection Practices (GACP) — appears in both WHO and EU regulatory guidance for herbal medicines. GACP governs cultivation and primary processing of plant material (including cannabis plants). It is a precondition for, not a substitute for, GMP. EU Annex 7 explicitly addresses the point at which post-harvest activities such as drying and cutting transition from GACP scope into GMP Part I or Part II territory. Operators need to understand where their GACP obligations end and their GMP obligations begin in the manufacturing process.

Implementing Both Standards: Practical Overlaps and Divergences

Despite their differences, GPP and GMP share significant structural overlap that operators can leverage to build one integrated quality infrastructure rather than two parallel systems.

Documentation architecture is shared. Both standards require written SOPs, records of implementation, and evidence of corrective action when things go wrong. An operator building robust GPP documentation is creating the foundation on which GMP’s more demanding documentation requirements can be constructed.

Personnel training is universal. GPP requires staff to understand and follow sanitation and production procedures. GMP requires documented, role-specific training programs with records. Building to GMP training standards from the outset costs little more than building to GPP minimums, and the records created serve both compliance programs.

Traceability is convergent. GPP requires lot-level tracking from seed through sale. GMP requires batch-level manufacturing records with complete chain of custody. A properly implemented seed-to-sale tracking system can satisfy both requirements simultaneously, provided the system itself is validated to GMP standards (Annex 11 / PIC/S requirements for computerized systems).

Where they genuinely diverge is in the depth of validation, the QP requirement, the formal pharmaceutical quality system, and the third-party certification process. These are not incremental improvements on GPP — they represent a qualitative shift in how quality is assured, documented, and verified by external authorities.

For a detailed breakdown of what a cannabis quality management system looks like in practice — and how it supports both GPP and GMP compliance environments — see GrowerIQ’s Cannabis Quality Management System Guide.

Understanding the regulatory context in which these standards operate is equally important. GrowerIQ’s analysis of Health Canada’s 2025 cannabis regulation amendments details the most recent changes to the Canadian framework that GPP-compliant operators must incorporate.

How GrowerIQ Supports GPP and GMP Compliance

Compliance with either standard ultimately rests on the reliability of your production records. A GPP inspection failure most commonly traces to documentation gaps — practices followed but not recorded, SOPs written but not implemented consistently. A GMP audit failure more often reflects system validation deficiencies, incomplete batch manufacturing records, or CAPA processes that exist on paper but lack evidence of systematic follow-through.

GrowerIQ’s seed-to-sale platform was designed to close both gaps. It provides:

• End-to-end lot and batch traceability from seed genetic origin through cultivation, harvest, processing, and product distribution — satisfying GPP’s lot tracking requirements and GMP’s batch manufacturing record obligations simultaneously.
• SOP enforcement with digital sign-off so that production steps cannot be marked complete without documented operator confirmation — creating the evidence trail both Health Canada inspectors and EU GMP auditors require.
• Integrated quality event management for deviations, CAPA, and change control — the CAPA infrastructure that GMP mandates and that GPP’s corrective action expectations also imply.
• Validated software architecture — GrowerIQ has been independently revalidated by RQC to meet EU GMP and PIC/S computerized system requirements under EudraLex Volume 4 Annex 11, providing the software validation documentation that GMP-stage audits require.
• Regulatory reporting aligned with Health Canada’s compliance expectations and international export documentation needs.

Whether your operation is building its GPP program for the first time, tightening documentation ahead of a Health Canada inspection, or pursuing EU GMP certification to access the German or UK market, the compliance infrastructure you choose determines how far and how fast you can scale.

This analysis is current as of May 2026 and draws on the Cannabis Regulations (SOR/2018-144) as published on the Justice Laws Website (current to 2026-03-31), Health Canada’s Good Production Practices Guide for Cannabis, EudraLex Volume 4 (European Commission/EMA, including Annex 7), WHO Technical Report Series TRS 986 Annex 2 (GMP for Pharmaceutical Products: Main Principles), and PIC/S GMP Guide PE 009-17. Figures reflect the best available data as of the publication date.

Sources

• Cannabis Regulations (SOR/2018-144), Part 5 — Good Production Practices, Sections 78.1–89 — Justice Laws Website, Government of Canada
• Good Production Practices Guide for Cannabis — Guidance Document — Health Canada
• Good Production Practices for Cannabis — Overview — Health Canada
• EudraLex Volume 4 — Good Manufacturing Practice (GMP) Guidelines — European Commission (EMA)
• EudraLex Volume 4, Annex 7 — Manufacture of Herbal Medicinal Products — European Commission (EMA)
• WHO TRS 986, Annex 2 — Good Manufacturing Practices for Pharmaceutical Products: Main Principles — World Health Organization
• WHO TRS 1010, Annex 2 — GMP for the Manufacture of Herbal Medicines — World Health Organization
• PIC/S Guide to Good Manufacturing Practice for Medicinal Products, PE 009-17 — Pharmaceutical Inspection Co-operation Scheme (PIC/S)
• Mutual Recognition Agreement — Canada and the European Union, Human Drug GMP Inspections — Health Canada
• GrowerIQ — GPP Canada 2026: Good Production Practice Requirements for Licensed Producers — GrowerIQ
• GrowerIQ — Why Is GMP Important in the Cannabis Industry? — GrowerIQ
• GrowerIQ — Canada Exports 240 Tonnes of Cannabis in 2025 — GrowerIQ